- Home
- ZVIA vs LPCN Comparison
ZVIA vs LPCN Comparison
Compare ZVIA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- LPCN
- Stock Information
- Founded
- ZVIA 2007
- LPCN 1997
- Country
- ZVIA United States
- LPCN United States
- Employees
- ZVIA N/A
- LPCN N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- LPCN Health Care
- Exchange
- ZVIA Nasdaq
- LPCN Nasdaq
- Market Cap
- ZVIA 204.8M
- LPCN 16.1M
- IPO Year
- ZVIA 2021
- LPCN N/A
- Fundamental
- Price
- ZVIA $2.96
- LPCN $3.00
- Analyst Decision
- ZVIA Hold
- LPCN Strong Buy
- Analyst Count
- ZVIA 2
- LPCN 2
- Target Price
- ZVIA $3.38
- LPCN $9.00
- AVG Volume (30 Days)
- ZVIA 1.2M
- LPCN 29.3K
- Earning Date
- ZVIA 08-06-2025
- LPCN 08-07-2025
- Dividend Yield
- ZVIA N/A
- LPCN N/A
- EPS Growth
- ZVIA N/A
- LPCN N/A
- EPS
- ZVIA N/A
- LPCN N/A
- Revenue
- ZVIA $154,273,000.00
- LPCN $3,674,834.00
- Revenue This Year
- ZVIA $5.70
- LPCN N/A
- Revenue Next Year
- ZVIA $6.76
- LPCN N/A
- P/E Ratio
- ZVIA N/A
- LPCN N/A
- Revenue Growth
- ZVIA N/A
- LPCN N/A
- 52 Week Low
- ZVIA $0.73
- LPCN $2.68
- 52 Week High
- ZVIA $4.99
- LPCN $7.61
- Technical
- Relative Strength Index (RSI)
- ZVIA 49.50
- LPCN 40.07
- Support Level
- ZVIA $2.60
- LPCN $3.10
- Resistance Level
- ZVIA $3.04
- LPCN $3.39
- Average True Range (ATR)
- ZVIA 0.25
- LPCN 0.18
- MACD
- ZVIA -0.06
- LPCN -0.00
- Stochastic Oscillator
- ZVIA 33.96
- LPCN 0.00
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.